GleamWall
中文EN

IMA ImageneBio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1835579 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-0.2%
TTM EPS YoY83.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-32.3%
ROA-28.6%
ROIC (approx.)-98.2%
Asset turnover—

Leverage & solvency

Liabilities / assets10.1%
Debt / equity0.00x
Current ratio16.17x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$800,000$3.50M
R&D expense$28.52M$32.11M
SG&A expense$20.73M$8.39M
Operating income-$48.45M-$37.00M
Pretax income-$45.70M-$36.55M
Income tax-$350,000$13,000
Net income-$45.35M-$36.57M
EBITDA-$48.05M-$35.90M
EPS (basic)-9.64-22.10
EPS (diluted)-9.64-22.10
Weighted avg. shares (diluted)—48.26M
Balance sheet
Cash & equivalents$94.53M$12.12M
Short-term investments$40.82M$0
Current assets$140.29M$12.47M
PP&E, net$0$8,000
Total assets$152.98M$15.92M
Current liabilities$11.23M$17.21M
Short-term debt$0$7.50M
Total liabilities$19.84M$17.45M
Shareholders' equity$133.14M-$160.56M
Shares outstanding—48.26M
Cash flow statement
Operating cash flow-$47.84M-$21.32M
Investing cash flow-$5.81M$11.12M
Financing cash flow$135.47M$6.91M
Depreciation & amortization$400,000$1.10M
Stock-based compensation$15.39M$0

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.